Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intellia Thera CS
(NQ:
NTLA
)
22.63
-0.24 (-1.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Intellia Thera CS
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
3 Beaten-Down Stocks That Could Soar This Year
March 18, 2023
These stocks could enjoy big rebounds in 2023.
Via
The Motley Fool
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
March 17, 2023
There are no guarantees that any stock will generate huge returns. But the odds look pretty good for these three growth stocks.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
March 14, 2023
Via
Benzinga
Analyst Ratings for Intellia Therapeutics
March 14, 2023
Via
Benzinga
Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today?
March 02, 2023
Huge opportunities also meets unignorable risks
Via
InvestorPlace
Why Intellia Therapeutics Stock Jumped This Week
March 02, 2023
Intellia Therapeutics landed a historic regulatory nod from the FDA.
Via
The Motley Fool
Intellia Therapeutics Earnings Perspective: Return On Capital Employed
February 28, 2023
Via
Benzinga
Top CRISPR Stocks
February 11, 2023
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.
Via
Talk Markets
2 Cathie Wood Stocks That Have Tripled Since the 2020 Market Crash
March 09, 2023
Are these stocks still good buys today?
Via
The Motley Fool
7 Cathie Wood Stocks for Your March Buy List
March 07, 2023
These top Cathie Wood stocks are just now attempting to pivot higher after a miserable outing for much of 2022.
Via
InvestorPlace
Stock Market Rally Rebounds Despite Rising Yields; Salesforce, Tesla In Focus: Weekly Review
March 03, 2023
Many leaders flashed buy signals as the indexes rebounded from support.
Via
Investor's Business Daily
Expert Ratings for Intellia Therapeutics
January 24, 2023
Via
Benzinga
Why Is Intellia Therapeutics Stock Trading Higher Today?
March 02, 2023
Intellia Therapeutics (NASDAQ: NTLA) shares are trading higher on Thursday after the company announced that the FDA cleared its Investigational New Drug application for NTLA-2002 for the treatment of...
Via
Benzinga
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
March 02, 2023
The FDA made a bold move in the CRISPR gene-editing realm.
Via
Investor's Business Daily
Better Buy: Beam Therapeutics or Intellia Therapeutics?
February 22, 2023
The two clinical-stage gene-editing companies have good long-term prospects.
Via
The Motley Fool
3 Deeply Undervalued Stocks That Could Double Your Money
February 15, 2023
These cutting-edge biotech stocks hold tremendous upside potential.
Via
The Motley Fool
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
February 07, 2023
These stocks are risky. But they just might deliver huge gains if analysts are right.
Via
The Motley Fool
Earnings Scheduled For February 23, 2023
February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Via
Benzinga
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
February 06, 2023
Cathie Wood is bullish about these stocks. And so are Wall Street analysts.
Via
The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
February 05, 2023
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
Via
Talk Markets
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
February 01, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
February 01, 2023
Via
Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
January 25, 2023
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.
Via
InvestorPlace
3 Gene Editing Stocks With the Best Long-Term Potential
January 25, 2023
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space
Via
InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
January 24, 2023
The growth-focused money manager is making moves.
Via
The Motley Fool
Stocks That Hit 52-Week Lows On Friday
January 20, 2023
Friday saw 23 companies set new 52-week lows.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023
January 24, 2023
Via
Benzinga
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years
January 07, 2023
Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023
January 19, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.